Simplification of antiretroviral treatment - How to sustain success, reduce toxicity and ensure adherence avoiding PI use

AIDS Reviews

Volumn 4, Issue 4, 2002, Pages 233-241

  Barreiro, Pablo ^a   García Benayas, Teresa ^a   Soriano, Vincent ^a   Gallant, Joel ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abacavir; Efavirenz; Lipodystrophy; Nevirapine; Nucleoside analogs; Protease inhibitors; Simplification

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; METHADONE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG DOSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG MIXTURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; GLUCOSE METABOLISM; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID STORAGE; LIPODYSTROPHY; LIVER TOXICITY; LONG TERM CARE; MAINTENANCE THERAPY; MENTAL DISEASE; METABOLIC DISORDER; MORBIDITY; MORPHOLOGY; NEUROLOGIC DISEASE; NEUROTOXICITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TOXICITY TESTING; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VIREMIA; VIRUS INHIBITION; VIRUS MUTATION;

HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 0036822456     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Hogg R, Heath K, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:51-58.
3. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
4. Van Leeuwen R. The Atlantic study: A randomized, open-label trial comparing two PI-sparing antiretroviral strategies versus a standard PI-containing regimen, 2 year follow-up data. 14th International AIDS Conference. Barcelona 2002 [abstract MoPeB3089].
5. Podzamczer D, Ferrer E, Consiglio E, et al. Final 12-month results from the COMBINE study: A randomized trial comparing combivir plus nelfinavir or nevirapine in naïve patients. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires 2001 [abstract 7].
6. Staszewski S, Morales-Ramírez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. N Engl J Med 1999;341:1865-73.
7. Arribas J, Pulido F, Miró J, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: The EfaVIP Study. AIDS 2002;16:1554-6.
8. Bartlett J, Johnson J, Herrera G, Sosa N, Rodríguez A, Shaefer M. Abacavir/lamivudine in combination with efavirenz, amprenavir/ritonavir or stavudine: ESS40001 (CLASS) preliminary 48 weeks results. 14th International AIDS Conference. Barcelona 2002 [abstract TuOrB1189].
9. Friedl A, Ledergerber B, Flepp M, et al. Response to first protease inhibitor- and efavirenz- containing antiretroviral combination therapy. The Swiss Cohort Study. AIDS 2001;15:1783-800.
10. Gallant J, Staszewski S, Pozniak A, et al. Favorable lipid and mitochondrial DNA profile for tenofovir disoproxil fumarate compared to stavudine in combination with lamivudine and efavirenz in antiretroviral therapy-naïve patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2002 [LB2].
11. Shafer R, Robbins G, Smeaton L, et al. Antiretroviral strategies in naïve HIV+ subjects: Comparison of 4-drug versus sequential 3-drug regimens (ACTG 384). 14th International AIDS Conference. Barcelona 2002 [abstract LbOr20B].
12. Matthews G, Sabin C, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: A cohort study. AIDS 2002;16:53-61.
13. Ghani A, Henley W, Donnelly C, Mayer S, Anderson R. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor containing regimens using observational databases. AIDS 2001;15:1133-42.
14. Bartlett J, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001;15:1369-77.
15. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults. JAMA 2001;285:1155-63.
16. Kirkland L, Fischl M, Tashima K, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral naïve, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis 2002;34:511-8.
17. Becker S, Rachlis A, Gill J, et al. Successful substitution of protease inhibitors with efavirenz in patients with undetectable viral loads -a prospective, randomized, multicenter, open-label study (DMP 049). 8th Conference on Retroviruses and Opportunistic Infections. Chicago 2001 [abstract 20].
18. Rey D, Schmitt M, Partisani M, et al. Efavirenz as a substitute for protease inhibitors in HIV-infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks. J Acquir Immune Defic Syndr 2001;27:459-62.
19. Hirschel B, Flepp M, Bucher H, et al. Switching from Pl to efavirenz: Differences in efficacy and tolerance among risk groups: A case-control study from the Swiss Cohort. AIDS 2002;16:381-5.
20. Treisman G, Kaplin A. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002;16:1201-15.
21. Clarke S, Mulcahy F, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001;33:1595-7.
22. Clarke S, Mulcahy F, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001;51:213-7.
23. Fumaz C, Tuldra A, Ferrer M, et al. Quality of life, emotional status, and adherence of HIV-infected patients treated with efavirenz versus Pl-containing regimens. J Acquir Immune Defic Syndr 2002;29:244-53.
24. Knechten H, Stürner K, Höhn C, Braun P. Switch to efavirenz in protease inhibitor-containing regimens. HIV Clinical Trials 2001;2:200-4.
25. Wu A, Rubin H, Matheus W, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Med Care 1997;29:786-98.
26. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with HIV: Prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-9.
27. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. J Acquir Immune Defic Syndr 2001;27:229-36.
28. Masquelier B, Neau D, Chêne G, et al. Mechanism of virological failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2001;28:309-12.
29. Dieleman J, Sturkenboom M, Wit F, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among HIV-infected patients with virus suppression. J Infect Dis 2002;185:1261-8.
30. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
31. Cohen S, Hassan S, Lapointe B, Mount B. Quality of life in HIV disease as measured by the McGill quality of life questionnaire. AIDS 1996;10:1421-7.
32. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy. Role of Hepatitis C and B infections. Hepatology 2002;35:182-9.
33. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based HAART in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
34. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in HIV infection. J Infect Dis 2002;185:1251-60.
35. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from PI to NVPor to EFV in patients with HIV infection and long-lasting viral suppression. Clin Infect Dis 2002;32:504-10.
36. Maggiolo F, Migliorino M, Maserati R, et al. Simplified therapeutic strategies in PI-experienced patients successfully treated with HAART. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago 2001 [abstract I-1916].
37. Martínez E, Podzamczer D, Ribera E, et al. Switching PI to NVP, EFV or ABC: A randomized, multicenter, open-label, simplification trial. 14th International AIDS Conference. Barcelona 2002 [abstract WeOrB1262].
38. Martínez E, García-Viejo M, Blanco J, et al. Impact of switching from HIV-1 protease inhibitors to efavirenz in successfully treated adults. Clin Infect Dis 2000;31:1266-73.
39. Estrada V, De Villar N, Martínez M, et al. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for HIV-infected patients with lipoatrophy. Clin Infect Dis 2002;35:69-76.
40. Moyle G, Baldwin C, Mandalia S, et al. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-positive patients. J Acquir Immune Defic Syndr 2001;28:399-401.
41. Haubrich R, Miller C, Gathe J, et al. The effect of NFV versus EFV on fasting lipid levels: Interim analysis from a prospective, randomized study in treatment naïve patients (AG1127). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2002 [abstract H-1914].
42. Martínez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
43. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002;16:1383-9.
44. Dubé M, Sprecher D, Henry W, et al. Preliminary guidelines for the evaluation and management dyslipidemia in adults infected with HIV and receiving antiretroviral therapy: Recommendations of the adult ACTG cardiovascular disease focus group. Clin Infect Dis 2002;31:1216-24.
45. Barbaro G, Klatt E. HIV infection and the cardiovascular system. AIDS Rev 2002;4:93-103.
46. Rozenbaum W, Defraissy J, Benata M, De Truchis P, Auton Z. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/ABC (French substudy, CNA30017). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco 2000 [abstract 47].
47. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicenter study. AIDS 2001;15:1811-22.
48. Fisac C, Fumero E, Crespo M, et al. Metabolic and body composition changes in patients switching from a PI-containing regimen to ABC, EFV or NVP. Twelve-month results of a randomized study (LIPNEFA). 14th International AIDS Conference. Barcelona 2002 [abstract ThPeB7354].
49. Fisac C, Fumero E, Crespo M, et al. A randomized trial of metabolic and body composition changes in patients switching from PI-containing regimens to ABC, EFV or NVP. 9th Conference on Retroviruses and Opportunistic Infections. Seattle 2002 [abstract 699-T].
50. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleotide analogs in patients with lipoatrophy: A randomised trial. JAMA 2002;288:207-15.
51. García-Benayas T, Blanco F, De la Cruz J, Soriano V, González-Lahoz J. Lipoatrophy improvement after switching from stavudine to abacavir. Antiviral Ther 2002;7:L39.